Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 94 | 116 | 137 | 141 | 138 | 161 | 157 | 146 |
| Operating profit | $m | 49.4 | 40.0 | ||||||
| Net profit | $m | -1.9 | 17.6 | 19.1 | 20.6 | 6.6 | -5.8 | 57.9 | 39.6 |
| EPS reported | $ | -0.91 | 3.91 | ||||||
| Operating cashflow per share | $ | 5.50 | 5.67 | ||||||
| Capex per share | $ | 6.11 | 19.85 | ||||||
| FCF per share | $ | -0.60 | -14.18 | ||||||
| Free cash flow | $m | -8 | -188 | ||||||
| Net debt | $m | 646 | 613 | ||||||
| Book value equity | $m | 510 | 657 | ||||||
| Book value per share | $ | 38.10 | 49.64 | ||||||
| Number of shares | m | 13.38 | 13.24 | ||||||
| DPS (TTM paid) | $ | 3.30 | 2.30 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 7.37 | ||||||
| P/B LTM | x | 0.92 | 0.66 | ||||||
| P/S LTM | x | 2.90 | 2.76 | ||||||
| P/FCF LTM | x | -57.89 | -2.30 | ||||||
| EV/EBITDA LTM | x | 11.57 | 6.60 | ||||||
| EV/Sales LTM | x | 6.95 | 6.67 | ||||||
| Earnings Yield LTM | % | -1.25% | 13.57% | ||||||
| FCF Yield | % | -1.73% | -43.40% | ||||||
| Quality | |||||||||
| ROE | % | -1.14% | 10.77% | ||||||
| ROIC | % | 3.97% | 24.98% | ||||||
| Operating margin | % | 30.66% | 25.50% | ||||||
| Gross margin | % | 6.41% | 0.39% | ||||||
| FCF/Sales | % | -5.02% | -119.70% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | +177.30% | ||||||
| Sales Growth YoY | % | +16.34% | +5.72% | ||||||
| Net Income Growth YoY | % | - | +463.13% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +51.08% | +0.65% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 12.43% | 7.98% | ||||||
| Dividend Growth | % | -21.43% | - | ||||||
| Payout Ratio | % | -477.45% | 93.72% | ||||||
| FCF/Debt | x | -0.01 | -0.29 | ||||||
| Net Debt/EBITDA | x | 6.73 | 3.95 | ||||||
| EBIT/Net interest | x | 1.11 | 1.11 | ||||||
| Net debt/market cap | % | 138.19% | 141.75% | ||||||
| Net debt/Equity | x | 1.27 | 0.93 | ||||||
| Gross debt/equity | x | 1.30 | 0.97 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Chiron is a real estate investment trust focused on investing in and actively managing critical healthcare infrastructure. With more than a decade of experience as a public company, it has built a diversified portfolio anchored by strong tenants who deliver essential care in their communities nationwide.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Chiron is a real estate investment trust focused on investing in and actively managing critical healthcare infrastructure. With more than a decade of experience as a public company, it has built a diversified portfolio anchored by strong tenants who deliver essential care in their communities nationwide.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free